What Verdica's 799 score means for AGIOS PHARMS INC
AGIOS PHARMS INC earns a composite score of 799 out of 850, placing it in the "strong" performance band (740–799). This score reflects consistent compliance across multiple regulatory dimensions tracked by state boards of pharmacy, the FDA, and the DEA.
Readers should interpret this as a provider with a solid regulatory track record. A score in this range indicates that AGIOS PHARMS INC has met or exceeded baseline licensing and operational standards, with no major unresolved compliance gaps flagged in public records. This is notably above the "acceptable" threshold (670–739) and well above elevated or high-risk zones. However, the score stops short of the "excellent" band (800–850), suggesting there are areas where performance either meets standards without distinction or where minor compliance matters prevent a higher ranking.
For business owners or consumers evaluating pharmacy providers, a 799 score signals a provider worth serious consideration, but not one that stands apart as exceptional. The underlying data sources—state board records, FDA filings, and DEA reporting—represent the regulatory backbone of pharmacy oversight, so a strong composite score carries meaningful weight.
How the sub-scores break down
Product Approval (850): This perfect sub-score indicates that all products AGIOS PHARMS INC distributes or manufactures carry appropriate FDA approval or clearance. In pharmacy, this is the baseline expectation; unapproved products or those with suspended approvals would substantially lower this metric. A score of 850 confirms full alignment with FDA product authorization requirements, with no red flags in the approval status of the entity's portfolio.
Manufacturer Profile (720): This is the lowest of the three sub-scores, though still solid. A manufacturer profile score of 720 reflects the entity's track record across facility inspections, quality systems, and production compliance as documented in state and federal records. This mid-range performance suggests AGIOS PHARMS INC operates within regulatory bounds but may have minor observations, cGMP (current Good Manufacturing Practice) considerations, or inspection findings that regulators have noted. A lower score in this dimension does not signal serious violations; rather, it indicates room for operational refinement.
FDA Compliance (830): This strong sub-score reflects adherence to federal pharmaceutical regulations, including adverse event reporting, labeling standards, and facility registration requirements. An 830 demonstrates that AGIOS PHARMS INC has few or no material compliance gaps in its federal regulatory filings and submissions.
What regulators track for pharmacy providers
State boards of pharmacy maintain licensure records, disciplinary histories, and operational permits for all licensed entities. They flag issues such as improper record-keeping, unauthorized product distribution, or violations of state-specific pharmacy laws.
The FDA monitors manufacturers and distributors through facility inspections, product approvals, and warning letters. Compliance scores reflect whether a provider has active approvals, unresolved inspection observations, or a history of recalls or enforcement actions. State board records cross-reference FDA findings.
The DEA tracks controlled substance handling, ordering, recordkeeping, and security compliance. Pharmacy providers must maintain exact inventories of scheduled drugs and report suspicious orders. Violations here—such as diversion, missing inventory, or improper prescriber verification—are serious compliance failures that substantially depress scores.
Together, these data sources create a regulatory profile. Scores move lower when providers accumulate findings, recalls, citations, or disciplinary actions. Scores remain strong when providers demonstrate consistent adherence across inspections, clean audit trails, and timely corrective actions.
Bottom line
AGIOS PHARMS INC is a strong-performing pharmacy provider with robust FDA product approval and solid federal compliance. The lower manufacturer profile sub-score warrants a closer look at recent facility inspection records or quality observations. Before committing to a partnership, cross-check the entity's specific state board standing and any recent FDA inspection summaries to understand what may be driving that 720 manufacturer score.